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Abstract: 
Background: Discovering biomarkers for dementia is a pivotal step towards successful early 
diagnosis and treatment. Although plasma biomarkers have been explored, no consensus has 
been reached. Alpha-synuclein (AS), a 14kDa synaptic protein associated with several 
neurodegenerative diseases, exists natively within erythrocytes (ERC). This protein is 
characteristic of Lewy Body diseases, in which it aggregates into toxic Lewy bodies. As 
erythrocytes are implicated in dementia, they are a potential target for future biomarkers.  
Aims: The aims of this study were to assess AS levels within ERC and whether AS can be 
used as a peripheral biomarker to differentiate between dementia and aged matched healthy 
control subjects.  
Methods: A total of 114 samples (60 ageing controls, 36 Alzheimer’s disease, 12 vascular 
dementia and 6 Dementia with Lewy Bodies subjects) were analysed. We used: Bradford 
assay to measure protein concentration, indirect ELISA to detect levels of AS and 
Immunoblotting to identify AS composition.  
Results: AS oligomers were present in dementia blood samples, whereas in controls, AS was 
largely monomeric. There was a significant increase in AS levels in DLB whole bloods 
(p=0.005), with a sensitivity and specificity of 100.0% and 93.9%. Protein concentrations in 
pH 5.7 ERC fractions were significantly increased in dementia patients compared to controls 
(17.58 vs. 40.33 μg/ml; p=<0.005). In the VaD group, the protein concentration in the pH5.7 
ERC fraction had sensitivity and specificity of 91.7% and 62.1%.   
Conclusions: Protein concentration and AS levels have a potential for development of a 
novel diagnostic dementia blood test. 
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Introduction 
Alpha-synuclein (AS) has emerged as one of the major neurobiological players in 
Parkinson’s Disease (PD) pathogenesis, with its’ aggregation in the form of misfolding, 
oligomerization and fibrillization extensively studied in PD and other synucleinopathies 
(reviewed in Wales et al, 2013, Lee et al, 2014). However, AS is also a widely distributed 
synaptic protein in the human brain, and found in various non-neuronal tissues, including 
muscle, liver, testis, blood vessels), and blood cells and derivates [e.g. plasma, serum, 
platelets, lymphocytes and erythrocytes (ERC)] (Nakai et al, 2007, Mukaetova-Ladinska et 
al, 2012), and skin fibroblasts (Hoepken et al, 2008). In contrast to the negligible amount of 
beta and gamma synuclein (Nakai et al, 2007), the ERC contain the highest amount of AS 
detected in the periphery (Barbour et al, 2008, De Palma et al, 2012).  This makes ERC a 
good substrate to determine the properties of this synaptic protein in both ageing and distinct 
forms of dementia, with a potential to monitor these changes with the progression of 
dementia. 
In our previous biochemical and neuropathological studies, we have shown that AS 
undergoes similar changes like other synaptic proteins, including synaptophysin, SNAP-25 
and syntaxin, with a transient up-regulation in the pre-clinical stages of dementia 
(Mukaetova-Ladinska et al, 2000a), and is incorporated into proteolysis stable intraneuronal 
deposits in the intermediate stages of Alzheimer’s disease (AD) pathology (Mukaetova-
Ladinska et al, 2000b) prior the generalised synaptic loss occurring in end stages dementia 
(Mukaetova-Ladinska et al, 2000a). These findings were recently confirmed in our AS study 
using platelets and plasma (Mukaetova-Ladinska et al, 2012), where the increase in platelet 
AS was associated with impairment in attention, calculation, abstract thinking, depression 
and apathy, all associated with the early changes in the dementia clinical phenotype.   
Since ERC contain about 95% of the AS found in the periphery (Barbour et al, 2008), the 
question arises whether these changes we have observed in platelets and in the brain tissue 
can be repeated using the AS derived from ERC. Argyriou et al (2012) found increased 
dimerization of ERC AS in people with Gaucher disease, a rare autosomal recessive disorder 
characterised by a deficiency of the lysosomal enzyme cerebrosidase, and parkinsonism. 
Argyriou et al (2012) also suggested that the increased AS dimer to monomer ratio in ERC 
may be a potential biomarker for Parkinson’s disease (PD) risk. These findings have been 
now confirmed in sporadic and genetic forms harbouring the GBA mutations, but not the 
SNCA (synuclein alpha gene) mutations in PD subjects (Papagiannakis et al, 2018). In 
addition, AS posttranslational modification also appear to be distinctly affected in the PD red 
blood cells (Vicente Miranda et al, 2018). Two most recent study expanded on these findings, 
reporting the alpha-synuclein to ERC protein ratio to discriminate well between the 
parkinsonian clinical syndromes (i.e. PD and multiple system atrophy; MSA) from normal 
ageing (Wang et al, 2015, Liu et al, 2018). These studies clearly indicate that ERC derived 
AS can not only be measured but may also have a clinical utility for diagnosis of PD and 
related clinical syndromes.  
In this study, we describe a protocol for extracting ERC-AS that can be used to measure AS 
in ERC. We report the presence of AS polymers in erythrocytes and whole bloods in subjects 
with dementia, and propose the clinical relevance of AS content in bloods 
 
Material and methods 
 
Participants’ demographic and clinical data 
The study was conducted on blood samples obtained from a total number of 114 subjects and 
included: 60 ageing control participants and 54 people with dementia [AD, n=36), Vascular 
dementia (VaD), n=12 and Dementia with Lewy Body (DLB), n=6]. We obtained 
demographic (gender and age) and extensive clinical data for all subjects enrolled in the 
study. Thus, both control and dementia subjects underwent cognitive assessment using the 
CAMCOG (Cambridge Cognitive Examination) and MMSE (Mini Mental State 
Examination), whereas dementia patients had additional assessments for their behaviour, 
which included NPI (Neuropsychiatric Inventory) and Cornell (Depression Scale) 
(Mukaetova-Ladinska et al, 2012) (Table 1). 
The analysed groups differed in respect to age, gender and cognitive status. The VaD and 
DLB participants were older than control and AD subjects (p=0.004) with more males in the 
AD group (p=0.010). Similarly, the VaD and DLB subjects had more pronounced cognitive 
impairment compared to control and AD subjects (p<0.005). In contrast, the dementia 
participants had equal extent of behavioural and mood problems, as measured with the NPI 
and Cornell depression rating scale, respectively (table 1).  
 
Blood Samples  
Blood samples were obtained following the clinical assessments and they were further 
processed to obtain 6 blood fractions from each blood sample: whole bloods (WB), ERC and 
ERC fraction, obtained at pH 5.7 as product of the platelet protocol, as described previously 
(Mukaetova-Ladinska et al, 2012), as well as their respective heat stable fractions.  
Whole Bloods: Whole blood samples were collected from the patient and 1ml sample was 
immediately frozen and stored at -8°C.  
Untreated ERC Fractions: 1ml of whole blood sample was subjected to centrifugation for 
20min at 13,000rpm at room temperature. The supernatant consisting of plasma was then 
removed leaving behind the ERC fraction which was then stored at -8°C.  
pH 5.7 ERC Fractions: The pH 5.7 ERC fraction was collected as a by-product of our 
platelet protocol (Mukaetova-Ladinska et al, 2012). Briefly, the whole blood samples were 
diluted in citric buffer (pH 5.7) by using a 1:5 ratio and centrifuged at 1000 rpm for 20 
minutes at 18°C. The pellet, containing ERCs, was collected and frozen at -8°C.  
Heat Stable ERC fractions: To obtain the heat stable fractions, whole blood and ERC 
samples were heated at 200°C for 5 minutes and centrifuged at 13,000 rpm for 15 minutes. 
The supernatant, consisting of the heat stable proteins, including native AS, was then 
collected and stored at -8°C, whilst the pellet, containing precipitated protein, was discarded.  
 
Protein Concentration  
The protein concentration for each analysed blood fraction was established using the 
Bradford Assay. A standard curve was produced using standard concentrations of bovine 
albumin serum (BSA), ranging from 0 μg/ml to 25 μg/ml. Untreated whole blood and ERC 
samples were diluted 1:1000 whereas the heat stable samples were diluted 1:150. The 
Coomassie protein assay solution, (Coomassie Plus- The Better Bradford protein assay, 
Thermo Scientific, Loughborough, UK), was then added to each of the wells and incubated 
on a shaker at room temperature for 10 minutes. OMEGA software was used to determine the 
protein concentrations at 595.  
SDS-PAGE and Immunoblotting 
Loading samples were prepared by mixing ERC preparations (40microgram/ml, determined 
using the Coomassie Plus-The Better Bradford protein assay, Thermo Scientific, 
Loughborough, UK, as per manufacturer’s instructions) with 2x SDS loading buffer [0.125M 
Tris pH 6.8, 4% SDS, 20% glycerol, 0.2M dithiothreitol (DTT), 0.02% bromophenol blue] to 
give the final protein concentration of 20microgram/ml and boiled for 5mins at 95°C. SDS-
PAGE was carried out using 17% acrylamide gels (OmniPAGE Mini Wide electroblotting 
module, SLS, UK), containing electrophoresis buffer (0.025M Tris, 0.192 M glycine, 0.1% 
w/v SDS] and ran at 100V for 1 hour at room temperature (RT). Gels were then immediately 
electroblotted using the Trans-Blot® Cell system (Bio-Rad), onto nitrocellulose membrane 
(pore size 0.45μm, Thermo Scientific Pierce, UK) while immersed in transfer buffer [0.4M 
glycine, 0.025M Tris, 5% w/v isopropanol] at a constant current of 350mA and 16°C for 2 
hours.   
Membranes were first blocked in blocking buffer consisting of 5% BSA in Tris-Buffered 
Saline and Tween-20 [TBST, 20mM Tris HCl pH 7.5, 150mM NaCl, 0.1% (w/v) Tween 20] 
for 1.5 hours at RT, then incubated with a primary antibody against the C-terminal end of 
alpha-synuclein {pAb -synuclein [(C-20)-R; SANTA CRUZ Biotechnology, INC] diluted 
1:100 in blocking buffer. The incubation with the primary antibody was carried overnight at 
4°C.  
The following day, membranes were washed thrice with TBST, each time for 10 minutes, and 
then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000, 
anti-rabbit-HRP P0448, DAKO Cytomation, Gostrup, Denmark) at RT for 1.5 hours diluted 
in TBST. The washing procedure was then repeated as above before products were visualised 
using a chemiluminescent kit (SuperSignal West Pico Chemiluminescent Substrate, Thermo 
Scientific, Rockford, IL) according to manufacturer’s instructions. The intensity of alpha 
synuclein products was visualised with a digital imager (ImageQuant LAS 4000, GE 
Healthcare, Buckinghamshire, UK), and the exposure was standardised to 30 seconds.  
 
ELISA alpha-synuclein immunoassay 
The level of ERC alpha-synuclein was measured with an indirect ELISA immunoassays, 
using the same commercial immunoprobe against the C-terminal end of alpha-synuclein 
{pAb -synuclein [(C-20)-R; SANTA CRUZ Biotechnology, INC] as per the SDS-PAGE, 
but used in 1:5000 dilution (Mukaetova-Ladinska et al, 2012).   Briefly, triplicates of double 
dilutions of the antigen (ERC; 13.5 microgram/ml); 1:20 dilution for the untreated blood 
samples and 1:100 dilution for the heat stable samples, which were diluted in coating buffer 
(carbonate-bicarbonate) over 12 wells were coated over night at 4ºC using carbonate-
bicarbonate buffer, and washed in 0.05% Tween, blocked with 1% dried skimmed milk and 
incubated for 1h at 37ºC.  Plates were washed and incubated for 1h at 37ºC with the primary 
antibody diluted in 0.05% Tween in phosphate buffer solution (PBS, pH 6.8). Following 
another wash in 0.05% Tween in PBS, plates were incubated with the secondary antibody 
conjugated to horseradish peroxidase (HRP) and incubated for 1h at 37ºC.  Colorimetric 
analysis of reaction with 3,3’,5,5’- trimethylbenzidine (TMB; Sigma) was performed, and 
reaction quenched after 10min with 2N H2SO4. Plates were read with Vmax plate-reader 
(Molecular Devices, Sunnyvale, California), and assay curves plotted using SOFTmaxPro 
(Version 4.7.1, molecular Devices, Sunnyvale, California). All values were expressed as 
relative arbitrary unites of immunoreactivity similar to previous reports (Mukaetova-
Ladinska et al, 2012).   
 
Statistical Analysis  
The data were analysed using SPSS v.21. Normality of data was established with the 
Kolmogorov-Smirnov Test. Since data were non-parametrically distributed we used non 
parametric analysis (Kruskal-Wallis test) to establish differences between dementia and 
control subjects, and mean rank values are presented. Sensitivity and specificity of protein 
concentration and AS measures was established with Receiver Operating Characteristics 
(ROC) curve, whereas the relationship between clinical measures of cognitive and 
behavioural changes and biochemical measures with regression analysis, Statistical 
significance was set at p ≤0.05. 
 
Results:  
 
AS detection in ERC and bloods 
AS was detected in all analysed groups at 14 kDa, predominantly in the monomeric form. 
The 14kDa band was strongly represented in all heat stable (Figure 1; lanes 1-3) compared to 
the untreated samples (Figure 1; lanes 4-6). In AD patients, less immunoreactive AS positive 
bands were also seen at approximately 28 kDa, which were not observed in the controls. 
Another band present in all fractions of AD samples was noted at 42 kDa, which was absent 
in the controls except from the untreated ERC fraction. There was a further band at 
approximately 56 kDa, which appeared in untreated ERC samples of both AD and control 
subjects (Figure 1).  
DLB and VaD subjects exhibited similar results to AD. Firstly, bands at 14 kDa were 
observed in all samples of both DLB and VaD, where a greater intensity of the bands was 
seen in the heat stable preparations (figure 1). Bands at approximately 28 kDa and 42 kDa 
were also noted in DLB and VaD cases.  However, they were absent in pH5.7 ERC 
preparations (lanes 2 and 2’; Figure 1).  The ~56 kDa were bands observed in all untreated 
but not in the heat stable preparations.  Unlike AD and control subjects, these were seen in all 
three fractions of VaD samples (lanes 4, 5 and 6) and WB and ERC preparations in DLB 
(Figure 1). 
 Protein Concentration Analysis  
The differences in protein concentration were largely seen within the ERC and pH 5.7 ERC 
fractions where most increases were evident in VaD and DLB dementia subjects. In untreated 
WB samples, the protein concentrations are similar for all cases irrespectively of their 
cognitive status (Table 2). However, in the ERC untreated fractions, the VaD group had 
significantly elevated protein concentration compared to their control, AD and DLB 
counterparts (p< 0.001). The heat stable ERC fractions had a similar level of protein 
concentration between control and AD subjects. In the pH 5.7 fractions there was an increase 
in protein concentrations across the three sub-types of dementia, compared to control subjects 
(p < 0.001), markedly so in the VaD samples which were increased by a factor of 2.5. The 
protein concentrations of the heat stable pH 5.7 ERC were similar in all analysed groups 
(Table 2). The protein concentration of 14.1 μg/ml in the pH 5.7 untreated samples showed a 
significant sensitivity of 91.7% and a specificity of 62.1% to discriminate VaD patients from 
control subjects (p = <0.001) (Figure 2a). 
DLB subjects had significantly lower protein levels in their heat stable preparations derived 
from whole bloods compared to the control, AD and VaD subjects (p= 0.02) (Table 2). 
However, the ROC curve analysis showed low sensitivity and specificity (Figure 2b). We 
also performed correlation analysis to determine the relationship between the protein 
concentrations detected in the untreated and heat-treated blood samples. It is of note that 
there is an inverse relationship between the heat stable and the untreated samples in the pH 
5.7 samples (r -0.353, p=0.01). This occurs in the dementia subjects but not in controls, 
showing that increase in protein concentration in the dementia group was not caused by a 
heat stable protein. This rules out the possibility that the increase in proteins was due to the 
increase in AS, a heat stable synaptic protein. 
Analysis of AS levels in bloods fractions 
The untreated whole blood samples had a significant increase in AS content in the DLB 
subjects compared to controls, AD and VaD participants (p = 0.024). This increase in AS in 
the DLB subjects showed a high sensitivity (100%) and specificity (93.9%) to discriminate 
DLB patients from controls, with a RV of 192.4. (Figure 2b) 
In the whole blood heat stable samples, the VaD subjects had significantly elevated AS levels 
(p=0.038), and similar, but not statistically significant increase was also seen in the DLB 
subjects (Table 3).  
 ROC curve analysis for the VaD group in the whole blood heat stable samples showed a 
sensitivity and specificity of 75% and 57.4%. (p=0.038; figure 2c). Similar high levels of 
sensitivity and specificity were obtained for the DLB subjects when whole blood heat stable 
fractions were analysed, but this did not reach statistical significance when compared to 
control subjects (figure 2b). 
Protein Concentration and AS content Analysis  
Analysis between the protein concentrations and the AS content data was carried out to 
identify relationships between the two and, in particular, if AS could be responsible for any 
changes occurring in the protein concentration.  
The heat stable protein concentrations and heat stable AS levels displayed two significant 
correlations. The first was seen in the ERC heat stable fractions, (for controls and all 
dementia subtypes), which exhibited a positive correlation with a coefficient value of 0.349 
between the two sample groups therefore indicating that as the protein concentration 
increased there was also an increase in the AS content. (p=0.040) The second significant 
correlation of 0.296 was observed in the pH 5.7 ERC fractions again suggesting that as the 
protein concentration increases the AS content increases. (p=0.037) Collectively, findings 
from this analysis showed that the AS levels were elevated in the ERC fractions when protein 
concentration increased (Table 4). 
The untreated protein concentrations and the untreated AS levels showed different results to 
the heat stable correlations. The only significant correlation displayed for the untreated 
samples is regarding the pH 5.7 fractions, where there was a negative correlation, with a 
value of -0.286 (p=0.047). This observation indicated that as the protein concentrations of the 
pH 5.7 untreated samples increased, the AS content decreased.  The pH 5.7 untreated fraction 
was noted to have the larger increase in dementia patients compared to controls. Therefore, 
this further demonstrates that AS was not responsible for this increase. 
Clinical relevance of AS blood content  
Regression analysis was used to explore the correlation between the levels of AS detected in 
the blood samples and the clinical data of the dementia patients and control subjects (Table 
5). This analysis showed that for the whole blood samples there was a positive correlation 
between age and AS level in all the cases (control and dementia patients; p=0.007), 
suggesting that AS increases with age. However, this finding was only found in controls, and 
there was no correlation when the dementia group was analysed separately. Interestingly, the 
opposing relationship was noted between age and pH 5.7 ERC for the whole and the control 
group.  
The cognitive assessment analysis (CAMCOG and MMSE) highlighted a negative 
relationship between the heat stable AS and the cognitive measures in the dementia group, 
but not in control subjects. This was especially evident in the ERC heat stable fraction. In 
addition, the global behavioural changes, as measured by NPI and Cornell test, were 
positively related to the heat stable AS in both the ERC and pH 5.7 ERC fractions (Table 5). 
Discussion  
The main findings from this study confirm that blood samples and ERC, in specific, could be 
reliable biomarkers for dementia. Thus, elevated protein concentration has high sensitivity 
and specificity to discriminate VaD subjects from normal ageing and other forms of 
dementia, such as AD and DLB. This significant increase in protein concentration was 
confined to the ERC fraction processed at pH 5.7 but was not evident in whole bloods or the 
ERC fraction alone. Furthermore, we demonstrate that this increase is not due to the 
upregulation of AS or other heat stable proteins. In addition to this, AS levels in the whole 
bloods are highly increased in DLB subjects, with high sensitivity and specificity for the 
disease, whilst the ERC AS measures do not appear to differ between control and dementia 
subjects. The reported findings for the DLB subjects, however, need to be interpreted with 
caution, since they derive from a small group of patients.  
This is the first report to recognise the role of protein concentration in relation to dementia 
(VaD) diagnosis. Although increases in individual proteins has been reported in bloods, this 
has been restricted to certain plasma proteins, identified either in proteomic studies (Liu et al, 
2015) or in studies exploring dementia-related blood proteins, e.g. inflammatory markers (α1-
antichymotrypsin, interleukin 6, and C-reactive protein) or AS (Engelhart et al, 2004, Kasuga 
et al, 2012). It appears that the by-product of the platelet preparation in pH 5.7 contributes to 
significant increase in the protein concentration in this fraction that does not occur when ERC 
are prepared as a result of one step centrifugation. This finding invites us to explore into 
possible proteins which could lead us to future potential biomarkers, specifically for VaD as 
the largest increase is seen here. ERCs contain several proteins that are also found in the 
brain; one of them is ferritin. This protein is found in blood and contains a ferric ion. 
Previous studies have shown that iron regulation in AD and PD can often be disturbed where 
levels of iron increase and cause disruptions to proteins such as AS (Eassa et al, 2009). 
Increased iron, is also found in subcortical ischaemic vascular dementia and its elevation 
corresponds to the cognitive impairment (Liu et al, 2015). Ferritin releases the ferric ion 
which can then interact with AS and causes mis-folding leading to aggregation and formation 
of Lewy Bodies (Liu et al, 2015) and AS synaptic loss. Furthermore, the AS  
coding gene possesses an iron regulatory element (IRE) which requires binding of iron to 
regulate it’s expression. The amyloid precursor protein (APP) also possesses an IRE which 
relates ferritin to both DLB and AD. Since iron is highly involved in various dementia 
pathologies, it needs to be explored further as a potential cause of elevated protein 
concentration (Cahill et al, 2009). A previous study reported a positive relationship between 
the severity of AD and aluminium ferritin (Cahill et al, 2009).  
Other candidates contributing to protein increases seen in VaD are the heat shock proteins. 
Due to their involvement in refolding misfolded proteins and thereby preventing aggregation, 
they have been reported to be upregulated in diseases such as dementia (Engelhart et al, 
2004). Proteomic studies are now needed to expand on this research to identify blood proteins 
which increase as a result of VaD pathology. This will help to understand the real nature of 
the overall increase in blood protein concentration in VaD and thus aid the development of 
diagnostic biomarkers for the disease.  
The increase in protein concentration in VaD subjects at pH 5.7 argues there is a specific 
phenomenon associated with this dementia subtype. If so, this may be closely associated with 
the increased blood viscosity leading to vascular events in these patients. Indeed, acidosis 
impairs blood flow properties and previous studies have described a possible decrease in pH 
caused by oxidative stress, which occurs in dementia (Reinhart et al, 2002, Mulkey et al, 
2004). This may lead to a sequential precipitation of a specific protein seen in the pH 5.7 
fractions. The inverse correlation between the heat stable and untreated pH 5.7 protein 
concentrations rules out the heat stable AS to contribute to this. Understanding this 
phenomenon is now a crucial step in elucidating the pathophysiological mechanisms 
underlying VaD.  
 
AS has been previously explored as a peripheral, blood biomarker for dementia. However, 
most of the studies have concentrated on plasma and in Parkinson’s disease (PD), with 
somewhat inconclusive results (Kasuga et al, 2012). Thus, an observed increase, decrease and 
unchanged AS plasma levels have all been reported in PD. However, increased plasma AS 
oligomers reflecting the Lewy body pathology, appear to be a more consistent finding in the 
bloods of PD subjects (El-Agnaf, et al, 2006). In all dementia blood samples that we 
analysed, we detected presence of oligomers and polymers, both in the whole blood and the 
ERC fractions. However, the ELISA method we used was able to address the total AS 
content in the blood samples and not AS polymers. Furthermore, the increase in AS in the 
DLB subjects was detected in the whole bloods, and not in ERC fractions. This suggests that 
the AS increase in the DLB group is a result of AS elevation either in plasma or other blood 
cellular components, such as platelets. However, a recent study also demonstrated an increase 
in total AS in sedentary people (Iofrida et al, 2017), raising an interesting hypothesis that this 
ERC AS increase may be confined to people with Lewy body diseases, i.e. PD/PDD and 
DLB, known to have significant motor impairment (Fritz et al, 2016). These findings now 
need to be explored further to determine both the exact blood fraction where the AS increase 
occurs, as well as determine the putative lifestyle factors that may additional influence the 
latter. This may well enhance the specificity of the current total AS blood measure to 
differentiate DLB from other dementia subtypes. However, we must point out both plasma 
(Gorostidi et al, 2012) and ERC (Abd-Elhadi et al, 2015) AS levels do not have a predictive 
value in the diagnosis of Parkinson’s disease and this has to be further investigated for DLB 
subjects.  
In contrast to Barbour et al, 2008, we found an increase of AS in the heat stable blood 
preparations. Furthermore, we provide further quantitative evidence for the increase in the 
heat stable AS throughout all analysed fractions of blood (Figure 1), using a much greater 
sample size of 114 compared to 4 young adult samples used in Barbour et al study (2008). It 
is of interest to point out that AS tetramers (56 kDa) but not smaller oligomers also occur in 
control subjects in the whole blood, but not heat stable fractions. Previous studies have shown 
that AS may exist natively as a tetramer which therefore explains the presence of the tetramer 
but no other oligomer, within the control subjects (Bartels et al, 2011). Both the qualitative 
(Western blot) and quantitative (ELISA) data of increased AS levels in the heat stable blood 
preparations are a further confirmation that AS in bloods undergoes self-polymerisation, with 
both oligomers, tetramers and higher molecular weight polymers present.  
The clinical analysis highlighted further the distinct contribution of monomeric (heat stable) 
and total AS content in blood samples. In contrast to the total AS content that appears to be 
able to discriminate between DLB and other forms of dementia and control subjects, the 
monomeric (heat stable) AS seems to be more closely related to the cognitive and 
behavioural profiles in subjects with dementia. More importantly, the increase in both protein 
concentration and AS in VaD and AD may be also driving the observed clinical relevance in 
our dementia cohort. In addition, a previous correlative clinico-biochemical study described a 
transient upregulation of AS in the temporal and frontal lobes of people with AD in mild to 
moderate stages (Mukaetova-Ladinska et al, 2000a). The AD group in the current study was 
mildly cognitively impaired, as demonstrated via the MMSE and CAMCOG scores. It is 
intriguing to speculate that blood AS measures may also be mirroring the central 
neuropathological process seen in AD.  
Our study is not devoid of limitations. Firstly, the sample sizes for different dementia sub-
types (e.g. DLB) were relatively small compared to AD and VaD. This meant that the results 
for the DLB cases needed to be analysed with caution as they may not represent the majority 
of DLB cases. The pharmacological heterogeneity of the analysed samples was not subjected 
to further analysis, and thus there is a possibility that medication may influence some of the 
results. In addition, heat stable samples could not be prepared from all ERC fractions largely 
due to the limited amount of available samples, with some samples showing signs of 
coagulation. Other studies have also reported limitations of their ERC work caused by the 
contamination of plasma within the separate fractions (Barbour et al, 2008). Since plasma 
also contains AS this harbour the potential of disrupting AS data, though we took great 
precautions to eliminate plasma especially from the ERC samples.  
 
In conclusion, we report novel clinical relevance of both blood protein concentration and AS 
content. One of our most significant findings was the potential use of whole bloods for 
dementia diagnosis, specifically DLB by monitoring AS levels. The replication in a larger 
sample size, will enable the use of archived blood material from previously conducted 
longitudinal studies on ageing and dementia to compare findings with neuropathological 
diagnosis.  
In addition to this, we were able to detect an elevation in the pH 5.7 treated ERC, specifically 
for VaD. We know from our work that the latter is not due to AS elevation. Overall the 
results from the current study have provided, an extensive clinical insight about the ERC 
derived AS and how it can facilitate the development of novel biomarkers for dementia. 
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Variable  Control AD VaD DLB F p 
Age/years  72.07±11.45 77.34±5.62 80.9±4.86 81.75±4.99 4.712 0.004 
Gender  
(M/F)  
15/45 21/15 7/5 4/2 13.920 <0.005 
CAMCOG  95.31±6.00 70.31±19.33 55.40±18.00 48.75±28.34 42.675 <0.005 
MMSE  27.89±2.026 21.29±5.829 15.90±5.174 12.00±8.29 40.210 <0.005 
NPI  NA 16.40±14.74 23.38±14.19 26.25±18.93 1.302 0.282 
Cornell  NA 6.06±4.54 5.75±2.71 2.50±1.92 1.311 0.280 
Table 1: Demographic and clinical data of the subjects.  Numbers represent mean ±SD. 
Abbreviations: AD, Alzheimer disease, VaD, vascular dementia; DLB, dementia with Lewy 
body; CAMCOCG, MMSE, Mini Mental State Examination; NPI, Neuropsychiatric 
Inventory; Cornell, Cornell Scale for Depression in Dementia; NA, data not available; M, 
male; F, female. 
 
  
Variables Control AD VaD DLB P 
 
WB  
Untreated   63.45 42.29 66.77 87.50 0.002 
Heat Stable  58.20 56.96 73.31 38.67 0.191 
ERC  
Untreated  
 
52.61 37.50 81.00 78.00 <0.001 
Heat Stable  
 
18.79 18.18 NA NA 0.862 
pH 5.7 ERC  
Untreated  
 
17.58 33.75 40.33 27.83 <0.001 
Heat Stable  
 
28.54 21.75 21.25 34.50 0.224 
Table 2: Protein concentrations in blood samples.  Heat stable samples were not available 
for VaD and DLB ERC fractions due to both a limited amount of ERC available and samples 
having a higher tendency to coagulate. All values expressed in μg/ml.  Abbreviations: ERC, 
erythrocytes; NA, not available; WB, whole blood.  
 
  
 Control AD VaD DLB p 
WB  
Untreated  49.73 50.72 56.05 97.00 0.024 
Heat Stable  48.71 50.06 72.31 60.50 0.180 
ERC  
Untreated  50.44 39.56 55.73 45.63 0.221 
Heat Stable  21.00 14.84 NA NA 0.075 
pH 5.7 ERC  
Untreated  28.20 25.81 20.71 16.25 0.277 
Heat Stable  26.42 24.44 23.32 27.20 0.927 
 
Table 3 –AS levels in blood fractions. Kruskal-Wallis analysis.  Values refer to relative 
values. Abbreviations: ERC, erythrocytes; WB, whole bloods. 
  
Parameters Statistical 
measures  
PC RBC HS PC WB HS PC pH 5.7 HS 
RBC HS  ρ  
Sig.  
 
0.349 
0.040 
 
-0.195 
0.261 
 
NA 
WB HS  ρ  
Sig.  
 
-0.086 
0.620 
 
-0.032 
0.749 
 
0.066 
0.684 
 
pH 5.7 HS  ρ  
Sig.  
 
NA 
 
0.169 
0.240 
 
0.296 
0.037 
Table 4 – Summary of correlations between the heat stable protein concentrations (PC) and 
the heat stable AS content. The data refer to all analysed samples grouped together. 
  
Variables AGE CAMCOG MMSE NPI Cornell 
WB  0.304 
0.005 
-0.020 
0.845 
-0.035 
0.728 
- 
- 
- 
- 
C  0.265 
0.007 
-0.05 
0.724 
-0.005 
0.971 
- 
- 
- 
- 
D  -0.055 
0.711 
-0.056 
0.710 
-0.109 
0.465 
0.193 
0.199 
0.100 
0.508 
WB HS  -0.101 
0.320 
-0.149 
0.142 
-0.193 
0.056 
- 
- 
- 
- 
C  -0.135 
0.440 
0.215 
0.121 
0.107 
0.446 
- 
- 
- 
- 
D  0.086 
0.569 
-0.131 
0.390 
-0.196 
0.196 
0.088 
0.565 
0.075 
0.606 
ERC  0.044 
0.683 
0.057 
0.601- 
0.019 
0.862 
- 
- 
- 
- 
C  .0440 
0.683 
0.271 
0.082 
0.233 
0.137 
- 
- 
- 
- 
D  0.044 
0.773 
-0.120 
0.444 
-0.123 
0.431 
-0.174 
0.265 
0.060 
0.703 
ERC HS  -0.135 
0.440 
0.340 
0.046 
0.251 
0.147- 
- 
- 
- 
- 
C  -0.135 
0.440 
0.268 
0.282 
0.365 
0.136 
- 
- 
- 
- 
D  -0.053 
0.839 
-0.538 
0.026 
-0.499 
0.041 
-0.174 
0.265 
0.452 
0.069 
pH 5.7 ERC  -0.455 
0.003 
0.182 
0.262 
0.179 
0.270- 
- 
- 
- 
- 
C  -0.64 
0.003 
0.012 
0.961 
0.062 
0.794 
- 
- 
- 
- 
D  0.085 
0.693 
-0.143 
0.559 
-0.113 
0.646 
0.330 
0.195 
0.038 
0.881 
pH 5.7 ERC 
HS  
0.013 
0.935 
-0.095 
0.561 
-0.179 
0.268 
- 
- 
- 
- 
C  -0.065 
0.786 
-0.104 
0.662 
-0.098 
0.608 
- 
- 
- 
- 
D  -0.165 
0.431 
0.036 
0.887 
0.057 
0.821 
0.655 
0.003 
0.437 
0.070 
Table 5 – Summary of regression analysis of clinical data and AS content in different blood 
fractions. Β value defines the regression coefficient whilst p defines the level of significance. 
Abbreviations: C, control subjects; D, dementia subjects.  
 
  
  
 
 
 
 
 
Figure 1: Alpha synuclein (AS) immunoreactivity in ERC fractions. Western blot. Lanes 1 – 
3 WB, pH 5.7 ERC and ERC heat stable preparations. Lanes 4 – 6 contain untreated WB, pH 
5.7 ERC and ERC fractions. Markers on the left show the approximate molecular weight of 
the bands.  This was repeated X times with similar results? 
  
a)  
b)
 
c)
 
 
 
Figure 2: a) ROC (Receiver Operation Characteristics) Curve for protein concentration, 
showing sensitivity and specificity (91.7%, 62.1%) of pH 5.7 samples for VaD subjects in 
blue (p = <0.005). This was not the case for the heat stable fraction of pH 5.7 ERC (in green). 
b) Graph showing the AS measures sensitivity and specificity of the whole blood (100%, 
93.9%) and whole blood heat stable (87.5%, 56.4%) samples for DLB. AS content in blue 
and green respectively. 
c) ROC Curve analysis for the AS measures in VaD WB HS fraction. Sensitivity and 
Specificity of 75% and 57.4% (p=0.038). 
 
 
